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E-mail address: keith.willison@icr.ac.uk (K.R. WilliActin is dependent on the type-II chaperonin CCT (chaperonin containing TCP-1) to reach its native
state. In vitro, yeast CCT folds yeast and also mammalian cytoplasmic (b/c) actins but is now found to
be incapable of folding mammalian skeletal muscle a-actin. Arrest of a-actin on yeast CCT at a fold-
ing cycle intermediate has been observed by electron microscopy. This discovery explains previous
observations in vivo that yeast mutants expressing only the muscle actin gene are non-viable. Muta-
tional analysis identiﬁed a single speciﬁc a-actin residue, Asn-297, that confers this species/isoform
folding speciﬁcity. The implications of this incompatibility for chaperonin mechanism and actin–
CCT co-evolution are discussed.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
It is well established that actin, the key structural component of
the cytoskeleton, is unable to fold autonomously and requires
interaction with the cytosolic chaperonin CCT (chaperonin con-
taining TCP-1) to attain its native conformation. Chaperonin
dependence of a protein typically arises when autonomous folding
is kinetically or thermodynamically unfavourable or when a fold-
ing intermediate is aggregation-prone. This is alleviated by folding
within or around the chaperonin cavity which alters the substrate
free energy landscape and prevents intermolecular interactions.
The mechanism by which type-II chaperonins operate and speciﬁ-
cally how CCT folds actin is not yet properly understood, although
the requirement of actin for CCT is thought to be both aggregation-
preventing and thermodynamic in origin [1].
In higher eukaryotes several isoforms of actin exist, a-actins
which form sarcomer units with myosin ﬁlaments in muscle tissue
and b and c isoforms which form cytoskeletal networks. Mutations
in a-actin lead to clinically severe inherited muscular diseases [2].
Yeast has been used as an effective model to study the in vivo
effects of b- and c-actin mutations. However, it has not been pos-
sible to studymutant muscle actins in this way as a-actin is incom-chemical Societies. Published by E
r Research, 237 Fulham Road,
son).patible with yeast viability [3]. Here we demonstrate that the basis
of this incompatibility lies at the protein folding stage rather than
being a function of native state interactions. Further investigation
has revealed that the folding process is disrupted on yeast CCT,
and is caused by a single amino acid difference (N297) present in
a-actin with interesting implications for both folding mechanism
and the co-evolution of CCT and actin, one of its primary
substrates.2. Materials and methods
2.1. Puriﬁcation of CCT from the yeast Saccharomyces cerevisiae and
CCT–actin complexes
Yeast CCT was puriﬁed using a calmodulin binding peptide in-
serted into an internal loop in the apical domain of the CCT3 sub-
unit as an afﬁnity tag, as described previously [4]. Rabbit skeletal
muscle a-actin was isolated and puriﬁed as described [5]. His-
tagged yeast Plp2 was expressed in Escherichia coli and puriﬁed
over a Talon column (McCormack et al., unpublished data). For
EM visualization we used CCT-ANC2 (3CBP), harbouring the CBP-
tag in subunit CCT3 and mutation G345D in subunit CCT4. Muta-
tion G345D has been shown to exhibit reduced folding kinetics
without affecting the actin folding or actin–CCT interaction due
to perturbed ATP-allostery [6]. CCT–actin complexes were formedlsevier B.V. All rights reserved.
Fig. 1. Interaction of in vitro expressed yeast and human actin with yeast CCT. Yeast
CCT in vitro folding assays of ACT1, yeast actin, and ACTA1, human skeletal a-actin.
After 20 min, 1 lg DNaseI was added and the reaction incubated for 10 min at 30 C
(D). Yeast actin binds and is folded by yeast CCT while a-actin binds CCT but is not
folded.
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CCT-ANC2(3CBP) and Plp2 in the presence of ATP and MgCl2 for
30 min at 30 C. Complexes were separated over a Superose 6 gel
ﬁltration column (GE Healthcare) in GF buffer (10 mM HEPES, pH
8, 150 mM KCl, 1 mM DTT, 0.01% LDAO, 10% glycerol) supple-
mented with ATP and MgCl2, and peak fractions were concentrated
to 6.4 mg/ml.
2.2. EM grid preparation and data analysis
CCT–actin complex preparation was diluted 1 in 175 in buffer
containing 4% glycerol. Typically, droplets of 3 ll were applied to
carbon coated quantifoil 1.2 grids, and stained with uranyl acetate.
The grids were examined in a FEI-T12 at 200 kV and 42000mag-
niﬁcation. Photos were taken with a Kodak SO163 at a typical defo-
cus of 1 lm, equivalent to a ﬁrst zero at 18.5 Å on average. These
were digitised on a Nikon scanner, using a summing factor of 3,
giving a Å/pixel ratio of 4.632. The data was ﬁltered at 100 Å with
no low-pass ﬁlter, normalised and masked using Imagic [7]. 2D-
alignment against a chosen reference set was performed in SPIDER
[8], followed by multi-statistical analysis (MSA) in Imagic. This was
repeated until no further improvement was observed. The data
was then split into side views and no-side views, the latter contain-
ing typical top views but also the less well deﬁned oblique views.
2.3. Actin mutation construction, in vitro protein expression and
folding assays
Controlled CCT–actin folding assays [4] and in vitro translation
assays [9] were performed as described previously. Yeast CCT fold-
ing assays were performed in 60 ll volumes at 30 C with the fol-
lowing order of addition: folding assay buffer (20 mM HEPES (pH
8), 150 mM KCl, 20% glycerol), ATP/ADP mix to ﬁnal concentration
of 1 mM/0.1 mM CCT (1 ll stock solution concentration between 5
and 20 mg/ml) and ﬁnally the in vitro translated actin substrate
(generally 10% or 15% of the ﬁnal reaction volume). Human a-actin
cDNA, ACTA1, and yeast ACT1 were translated in vitro in 35S-
methionine containing EcoProTM T7 coupled transcription/transla-
tion system made from fractionated E. coli extract (Novagen). The
TNT-T7 coupled rabbit reticulocyte lysate system (Promega)
was used for the mammalian CCT folding experiments. For both
the yeast and mammalian assays, aliquots were taken at set reac-
tion time-points and stored on ice until loading of the entire time-
course onto a single, pre-cooled native 6% (w/v) acrylamide gel
with 1 mM ATP added to the gel mix and 0.1 mM ATP added to
the running buffer (25 mM Tris, 190 mM glycine). Site directed
mutagenesis of the plasmid DNAs was achieved using mutant sin-
gle stranded primers (MWG) and the QuikChangeTM kit and proto-
col (Stratagene).3. Results
3.1. Skeletal muscle a-actin is not re-folded by yeast CCT
Actin species that are nascent/unfolded, folded or CCT bound
can be distinguished on the basis of their differing mobilities under
non-denaturing polyacrylamide gel electrophoresis. This has been
exploited to investigate in vitro CCT-mediated folding of actin by
producing radiochemically labelled nascent actin via incorporation
of 35S-methionine into the elongating polypeptide chains [4,9,10].
Translation in eukaryotic cell extract allows investigation of the
interaction between nascent actin and the endogenous CCT,
whereas a prokaryotic translation system must be supplemented
with puriﬁed CCT (e.g. from yeast). Human a skeletal muscle gene,
ACTA1 (which encodes identical amino acid sequence to rabbitskeletal muscle a-actin) was expressed in the yeast CCT enriched
E. coli extract system. Nascent a-actin was found to bind yeast
CCT but surprisingly, folded product was not released, unlike yeast
actin which is bound, folded and released (Fig. 1). This is unex-
pected as yeast CCT folds human b-actin under these same condi-
tions [4]. Furthermore, a range of other actin isoforms and species-
speciﬁc variants have been expressed in yeast strains and therefore
must be able to be folded by yeast CCT in vivo [11]. To test whether
an additional cytosolic component is required to assist the folding
and release of a-actin by yeast CCT, rabbit reticulocyte lysate was
added to the EcoPro-yeast CCT folding assay, after allowing the a-
actin to bind yeast CCT. No folding activity was observed (data not
shown), establishing that a sequence-speciﬁc effect intrinsic to the
actin–CCT interaction is responsible for the inability of yeast CCT to
fold a-actin. This discovery explains longstanding observations
that Saccharomyces cerevisiae strains expressing a-actin are non-
viable [3].
3.2. Imaging of rabbit actin bound to yeast CCT
To establish whether a-actin binds yeast CCT in the expected
conformation [12], a-actin–yeast CCT complexes were imaged by
negative stain electron microscopy. Complexes were formed by
incubating EDTA unfolded actin with yeast CCT in the presence
of ATP and co-factor Plp2 [10,13]. Plp2 is a phosducin-like protein
that is known to interact with CCT [10,13]. Plp2 increases the
amount of actin bound to CCT (McCormack et al., unpublished re-
sults). A total of 9423 particles were selected and classiﬁed. These
actin–CCT preparations showed a high percentage of oblique views
over side and top views. The orientations of CCT bound to EM-grids
is known to be dependent on ATP-status, and it is likely that the
presence of substrate also has an effect. One hundred and forty
classes were calculated (40 side views, 19 top views and 81 oblique
views) consisting of 60 particles each. The number of classes was
not reduced further to accommodate the known heterogeneity of
CCT particles [14]. Fig. 2 shows six classes of typical top views,
revealing density inside the CCT cavity that is asymmetrically dis-
tributed with respect to the eight subunit CCT ring. Within the
density inside the cavity one can always distinguish two halves
that are either in line or at a slight angle with respect to each other.
The similarity of these CCT top views with previously published
images of nucleotide-free mouse testis CCT–rabbit a-actin com-
plexes [12] suggests that rabbit a-actin binds the yeast CCT ring
in a similar conformation.
Fig. 2. CCT–actin complex imaged by negative stain EM. Shown are six typical top view classes (panels A–F) of 2D average images (top row) and their respective isolines
(bottom row). Panel G is a schematic drawing of the proposed interaction between actin and CCT in the open conformation (S and L refer to small and large domains of actin)
[12].
Fig. 3. The ACT1 mutation I297N inhibits the folding of actin by yeast CCT. Yeast
CCT in vitro folding assays of ACT1 and the mutant ACT1I297N. Unlike wild-type
yeast actin, ACT1I297N binds but is not folded by yeast CCT.
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modifying CCT folding
Human a-skeletal actin and yeast actin show 87% sequence
identity. The most straightforward explanation for the difference
in folding behaviour is that the variation of a single residue or mo-
tif disrupts folding by CCT. To test this hypothesis, residues en-
coded by the yeast actin gene, ACT1, were changed to their
human ACTA1 counterparts, ‘humanizing’ parts of yeast actin,
and the mutants tested in yeast CCT in vitro folding assays. To con-
strain this search, the 49 differing residues were cross-referenced
against all the actin isoforms known to be viable in yeast in vivo
or folded by yeast CCT in vitro, and also with the extensive list of
known viable ACT1 mutations (e.g. [4,11,15,16]). This procedure
identiﬁed 13 residues which are unique to a-skeletal muscle actin
compared to all the actins that are known to be folded by yeast
CCT (table 1). Of these, six were tested individually as well as a
selection of combination mutations, ACT1V5T,A6T, ACT1I10C,V103T,
ACTII10C, C17V,V103T and ACT1I10C, C17V,V103T, S201V.
3.4. The single residue, Asn-297, determines compatibility with yeast
CCT
Of the mutants tested, none displayed a difference in binding
and folding kinetics except ACT1I297N which bound but was not re-
leased by yeast CCT (Fig. 3 and data not shown). To verify that this
mutant actin was folding competent, ACT1I297N was expressed inTable 1
Residues classiﬁed as unique to a-actin compared to actin isoforms and mutants
known to be folded by yeast CCT.
ACTA1a ACT1 Location/CCT binding siteb






Asn-162 Val SD3 N site
Val-201 Ser SD4/Site II-CCT beta/epsilon
Asn-225 Glu SD4
Thr-260 Ala SD4/M site
Ile-267 Leu SD3/M site
Ile-287 Val SD3
Asn-297 Ile SD3
Residues in bold have been tested in this study.
a The ﬁrst two N-terminal residues of class II actins such as skeletal muscle a-
actin, Met-Cys, are removed prior to acetylation of the adjacent acidic residue,
consequently conventional numbering of the actin amino acid residues commences
at Asp-1.
b Site notation refers to those identiﬁed in previous in vitro studies [18,19].
c Although the N terminus has not been identiﬁed as a discrete CCT binding site,
deletion of the N terminal six residues of beta-actin creates a folding compromised
actin mutant that binds CCT but is not released [19].the mammalian rabbit reticulocyte lysate system (Fig. 4). Similar,
albeit slightly slower, folding kinetics to wild-type actin were ob-
served, demonstrating that the folding inhibition was speciﬁc to
yeast CCT.
To determine whether this residue alone was responsible for
conferring the species selectivity of yeast CCT, the corresponding
reverse mutation, N297I, was introduced into the human ACTA1
sequence. The mutant was expressed in the in vitro – yeast CCT
system and CCT binding and folding was observed (Fig. 5), con-
ﬁrmed by ability to bind DNaseI [4]. This demonstrates that the
single amino acid residue at position 297 determines whether a-
actin can be folded by yeast CCT.Fig. 4. The folding activity of rabbit CCT is similar for yeast actin, human alpha-
actin and both of the residue 297 point mutants. Folding assay of ACT1, ACT1I297N,
ACTA1 and ACTA1N297N in rabbit reticulocyte lysate. Folding activity by rabbit CCT
was observed for each amino acid sequence.
Fig. 5. A single mutation in human alpha-actin, N297I, restores the productive folding interaction with yeast CCT Yeast CCT in vitro folding assays of ACTA1, and the mutant
ACTA1N297I. After 50 min, 1 lg DNaseI was added and the reaction incubated for 10 min at 30 C (D). The presence of the N297I mutation allows human a-actin to be folded by
yeast CCT.
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Asparagine-297 is a muscle actin-speciﬁc residue, which is
substituted by threonine in mammalian non-muscle actins and
isoluecine or valine in invertebrates, plants, yeast and other single
celled organisms. Interestingly, this residue is not associated with
any intermolecular binding interactions and is buried within the
core of the protein, in one of four parallel beta-strands that form
a platform across subdomain-3 (Fig. 6). Four other muscle actin-
speciﬁc residues, N162, L153, M176 and M299, occur in the adja-
cent beta-strands. No role has yet been deﬁned for this region
but its proximity to the nucleotide binding cleft may permit inter-
action with the bound adenosine group. Such an internal scaffold is
more likely to be important in effecting tertiary conformation than
speciﬁc binding interactions. It should be noted that the same
structural, though not sequence, motif is observed in the internal
structure of sugar kinases and Hsc70, both members of the ‘ac-
tin-fold’ family [17].
N297 is not located within a described CCT binding site
[12,18,19]. However, previous studies have used CCT from mam-
malian sources. A deleterious folding effect associated with N297Fig. 6. The position of Asparagine-297 within the structure of alpha-actin. (a) Atomic stru
secondary structure, helix (red), sheet (yellow) and loop (green), the position of N297 (bla
(ball and stick) are bound in the cleft between subdomains 3/4 (the large domain) and 1/
within the internal beta sheet scaffold.would only be detected in an assay using non-N297 permissive
(i.e. yeast) CCT. Electron microscopy images of yeast CCT–rabbit
actin complexes were acquired to gain an understanding of the
mode of binding of a-actin to yeast CCT. The resulting top view
classes (Fig. 2) strongly suggest that the initial recognition process
remains unaffected and that binding occurs in the open conforma-
tion [12]. In none of the EM top view classes did we observe a com-
pact actin molecule, suggesting that rabbit actin cannot proceed
beyond the open conformation on yeast CCT. This implies that
the folding incompatibility emerges during the mid to late stages
of folding, or even at the stage of release of folded substrate. One
explanation is that N297 forms part of the binding site of an
uncharacterised folding intermediate. The residue is located within
a b-sheet that is protected by a-helices in the native structure but
may be exposed in an intermediate conformation, which would be
important if an aspect of CCT function is to protect exposed b-sheet
edges during substrate folding [20]. Alternatively, a change in this
residue may signiﬁcantly affect CCT-bound folding kinetics or ther-
modynamics. This could be due to perturbation of some local
hydrophobic collapse event, or reducing stability of the nucleotide
binding pocket of actin, thus affecting the overall stability of thecture of rabbit skeletal muscle G-actin (PDB code 1ATN) [23], coloured according to
ck) is indicated. Subdomains 1–4 are numbered; Ca2+ (purple sphere) and nucleotide
2 (the small domain). (b) Enlargement, highlighting the position of N297 (magenta)
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tion. In either case, the adaptation in rabbit CCT to accommodate
muscle actin also preserves the compatibility with the non-muscle
actins (i.e. the b and c isoforms).
Models to explain the evolution of CCT from a precursor, ther-
mosome-like protein and the emergence of hetero-oligomerism
have highlighted the possibility of co-evolution between subunits
and the major substrates, actin and tubulin of the eight CCT sub-
units [21]; the actin fold being introduced to CCT subsequent to
tubulin co-evolution by horizontal gene transfer from a Gram-neg-
ative bacterium [22]. Phylogenetic analysis has demonstrated that
the CCT-d and CCT-e subunits, which both associate with actin dur-
ing folding, are the latest evolving of the eight CCT subunits [21]. It
may be the case that further CCT–actin co-evolution, highlighted
experimentally here by the species speciﬁcity of CCT towards mus-
cle actin, opened the way for the subsequent divergence of the ac-
tin isoforms. Further investigation to uncover the corresponding
co-evolving elements in mammalian CCT will illuminate how the
CCT–actin systems generate diversity of actin function.
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